Providing patients with safe, proven effective treatment options is the goal of every orthopaedic surgeon, and the AAOS Clinical Practice Guidelines are designed to help you achieve that goal.
However, there are areas of practice where guidelines do not exist because the data to support them are unavailable. These data gaps can make it challenging to assure a patient that a particular therapy may be the best option or educate patients about therapies whose efficacy has not been established.
Through a partnership now in its third year, AAOS and the Orthopaedic Research and Education Foundation (OREF) are working to close those gaps. The OREF/AAOS Clinical Research Gaps Fund aims to identify and fund areas of clinical research for which there is a need for increased, targeted funding to evaluate the effectiveness of various orthopaedic interventions and ultimately improve the quality of care for patients. To help jumpstart the effort, AAOS made an initial financial investment in 2020 and a second contribution in 2021. Individual donors have contributed additional funds to support the grant program.
A request for applications for the first OREF/AAOS Injectable Orthobiologics of Knee Osteoarthritis Grant funded through this program opened in November 2020. The grant was awarded in July 2021 to Scott A. Rodeo, MD, FAAOS, orthopaedic surgeon and co-chief emeritus of the Sports Medicine Institute at Hospital for Special Surgery and professor of orthopaedic surgery at Weill Cornell Medical College, both in New York City. Dr. Rodeo will serve as principal investigator for the study, “Platelet-rich Plasma Treatment of the Anterior Cruciate Ligament (ACL)-injured Knee to Decrease the Risk of Post-traumatic Osteoarthritis.” A second grant, which opened in November 2021, will be awarded this spring.
“We were excited to fund the first grant in what we hope will be a long-term partnership to close gaps in our clinical knowledge of how to treat musculoskeletal issues that adversely affect both the patient and society,” said Richard F. Kyle, MD, FAAOS, president of OREF.
“Together with our partners at OREF, we look forward to the research that Dr. Rodeo and his team will conduct through this grant,” said AAOS President Daniel K. Guy, MD, FAAOS. “There is great interest in the potential of novel treatment of musculoskeletal conditions. This particular study of the use of an injectable orthobiologic, platelet-rich plasma, for a common knee ligament injury may lend insight into treatments to either prevent or minimize the later development of osteoarthritis of the knee. The Academy is delighted to participate in this inaugural research endeavor.”
For more information about AAOS’ investment in orthobiologics, visit www.aaos.org/quality. Donors interested in earmarking funds to further enable AAOS-prioritized clinical research needs within musculoskeletal healthcare may contribute to the OREF/AAOS Clinical Research Gaps Fund. Visit the OREF booth in Academy Hall or go to www.oref.org/aaoscpg to make a secure online donation.